Counterpoint Mutual Funds LLC bought a new position in The Chemours Company (NYSE:CC - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 27,583 shares of the specialty chemicals company's stock, valued at approximately $316,000.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. UMB Bank n.a. increased its holdings in Chemours by 73.9% in the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 948 shares in the last quarter. Brown Advisory Inc. increased its holdings in Chemours by 6.0% in the 1st quarter. Brown Advisory Inc. now owns 20,874 shares of the specialty chemicals company's stock worth $282,000 after purchasing an additional 1,174 shares in the last quarter. Inspire Investing LLC increased its holdings in Chemours by 5.7% in the 1st quarter. Inspire Investing LLC now owns 25,156 shares of the specialty chemicals company's stock worth $340,000 after purchasing an additional 1,357 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 1,444 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Chemours by 11.2% in the 4th quarter. BNP Paribas Financial Markets now owns 14,688 shares of the specialty chemicals company's stock worth $248,000 after purchasing an additional 1,481 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company's stock.
Insider Activity at Chemours
In other Chemours news, CEO Denise Dignam bought 4,068 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the transaction, the chief executive officer directly owned 191,546 shares in the company, valued at approximately $2,310,044.76. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.47% of the stock is currently owned by insiders.
Chemours Stock Down 0.7%
Shares of Chemours stock opened at $16.37 on Thursday. The Chemours Company has a one year low of $9.13 and a one year high of $22.38. The company has a debt-to-equity ratio of 17.16, a current ratio of 1.68 and a quick ratio of 0.83. The stock's 50-day moving average is $14.72 and its 200 day moving average is $12.92. The firm has a market cap of $2.45 billion, a price-to-earnings ratio of -5.85 and a beta of 1.61.
Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, beating the consensus estimate of $0.46 by $0.12. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The company had revenue of $1.62 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the prior year, the company earned $0.38 EPS. The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that The Chemours Company will post 2.03 EPS for the current year.
Chemours Cuts Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 15th were given a dividend of $0.0875 per share. The ex-dividend date was Friday, August 15th. This represents a $0.35 annualized dividend and a dividend yield of 2.1%. Chemours's dividend payout ratio is presently -12.50%.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on CC shares. Royal Bank Of Canada upped their target price on Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a report on Thursday, July 3rd. Zacks Research raised Chemours from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Truist Financial increased their price target on Chemours from $18.00 to $21.00 and gave the company a "buy" rating in a research note on Tuesday, September 16th. Mizuho increased their price target on Chemours from $16.00 to $19.00 and gave the company an "outperform" rating in a research note on Tuesday. Finally, Barclays decreased their price target on Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 28th. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Chemours presently has a consensus rating of "Moderate Buy" and an average price target of $17.63.
View Our Latest Report on CC
Chemours Profile
(
Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
See Also
Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
